<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Par22">Adult patients were included in the study if they were hospitalized for AIS between April 1, 2021 and September 30, 2022 and had a diagnosis of COVID-19 up to 30 days before the diagnosis of AIS (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The TriNetX codes used to identify COVID-19 diagnosis, AIS, and hospitalization are available in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>. Patients were excluded from the study if (1) hospitalization for AIS occurred before April 1, 2021 or after September 30, 2022 or (2) there was no COVID-19 diagnosis within 30 days before hospitalization for AIS.<fig id="Fig2"><label>Fig. 2</label><caption><title>Study design.</title><p>Patients hospitalized with a diagnosis of AIS and who had COVID-19 infection in the preceding one month were categorized into two groups based on COVID-19 vaccination status. They were compared at 7 and 30 days after admission for the outcomes of interest listed.</p></caption><graphic xlink:href="41541_2025_1158_Fig2_HTML" id="d33e1589"/></fig></p>